Verification evidence is still being completed.
PDF / print export
Biohit
Helsinki, Finland
- Verified lead
- Jussi Hahtela
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Gastrointestinal Diagnostics, Cancer-Risk Screening Support, Acetaldehyde Testing, and Clinical Laboratory Products
- Review cycle
- May 2026
- Full address
- Laippatie 1, FI-00880 Helsinki, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Biohit contact page confirming the Helsinki operating address.
- Editorial note
- Biohit is published because official investor and company materials confirm current leadership, Helsinki operating footprint, and a clear diagnostics platform with clinical and preventive-health relevance.
Gastrointestinal Diagnostics, Cancer-Risk Screening Support, Acetaldehyde Testing, and Clinical Laboratory Products
Public-company investor disclosure, Official Helsinki contact disclosure, Clinical diagnostics and laboratory-products platform claim
Biohit is published because official investor and company materials confirm current leadership, Helsinki operating footprint, and a clear diagnostics platform with clinical and preventive-health relevance.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Helsinki, Finland
Biohit
Gastrointestinal Diagnostics, Cancer-Risk Screening Support, Acetaldehyde Testing, and Clinical Laboratory Products · Commercial diagnostics platform
Biohit runs gastrointestinal diagnostics, clinical test product development, and preventive screening support in Helsinki, Finland.
- Lead
- Jussi Hahtela (verified ↗)
- Address
- Laippatie 1, FI-00880 Helsinki, Finland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Commercial diagnostics platform
- Capabilities
- Gastrointestinal Diagnostics · Clinical Test Product Development · Preventive Screening Support
- Founded
- 1988
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Jussi Hahtela
CEO
Full addressLaippatie 1, FI-00880 Helsinki, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Biohit contact page listing the Laippatie 1 Helsinki address.
Open sourceCommercial diagnostics platform
Helsinki, Finland. Gastrointestinal Diagnostics, Cancer-Risk Screening Support, Acetaldehyde Testing, and Clinical Laboratory Products. Review completed on 21 Mar 2026.
Finnish corporate governance and clinical-diagnostics oversight
Public-company investor disclosure, Official Helsinki contact disclosure, Clinical diagnostics and laboratory-products platform claim
Gastrointestinal Diagnostics, Cancer-Risk Screening Support, Acetaldehyde Testing, and Clinical Laboratory Products
Biohit is published because official investor and company materials confirm current leadership, Helsinki operating footprint, and a clear diagnostics platform with clinical and preventive-health relevance.
Editorial note
Biohit is published because official investor and company materials confirm current leadership, Helsinki operating footprint, and a clear diagnostics platform with clinical and preventive-health relevance.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Gastrointestinal Diagnostics
Clinical Test Product Development
Preventive Screening Support
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical diagnostics workflow
Test-product development infrastructure
Laboratory products platform
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Biohit located?
- Biohit operates from Laippatie 1, FI-00880 Helsinki, Finland, Helsinki, Finland.
- Who runs Biohit?
- Biohit is led by Jussi Hahtela, CEO. Verified 21 Mar 2026.
- What does Biohit do?
- Biohit runs gastrointestinal diagnostics, clinical test product development, and preventive screening support in Helsinki, Finland. Core capabilities: Gastrointestinal Diagnostics, Clinical Test Product Development, Preventive Screening Support.
Editorial context
Related technical briefs
Briefs that name Helsinki as a covered market or city.